[CAS NO. ]  SARS-CoV-2-IN-27 disodium

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS

Catalog
HY-151271A
Brand
MCE
CAS
-

DESCRIPTION

Overview

MDL-
Molecular Weight938.93
Molecular FormulaC54H54Na2O8P2
SMILESCCCCCCOP(OC(C1=C2C3C4=CC(C5CC6C7=C5C=CC=C7)=C6C=C4C1C3)=C(C8C9=C(C%10C8)C=C%11C(C%12C%13=C(C%11C%12)C=CC=C%13)=C9)C%10=C2OP(OCCCCCC)(O[Na])=O)(O[Na])=O

For research use only. We do not sell to patients.

Summary

SARS-CoV-2-IN-27 disodium is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 disodium exhibits antiviral activity with IC 50 s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 disodium induces liposomal membrane disruption with an EC 50 value of 6.5 μM [1] .


IC50 & Target

IC50: 6.5 μM (viral liposome, SARS-CoV-2) [1]


In Vitro

SARS-CoV-2-IN-27 (CP019) disodium inhibits SARS-CoV-2 (IC 50 =1.7 μM) with few cytotoxicity (Caco2 cells, CC 50 =208 μM) [1] .
SARS-CoV-2-IN-27 disodium (0-15 μM; 2 h) inactivate SARS-CoV-2, shows inhibition against infection with an IC 50 value of 1.0 μM [1] .
SARS-CoV-2-IN-27 disodium suppresses varies enveloped viruses activity with IC 50 s of 7.4 μM (respiratory syncytial virus, RSV), 112.6 μM (influenza A virus, IAV), 4.6 μM (measles virus, MeV), 1.8 μM (herpes simplex viruses, HSV-1), respectively [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay [1]

Cell Line: Caco2 cells exposed with SARS-CoV-2 (2 h, 37 ℃)
Concentration: 0, 0.23, 0.93, 3.75, 15 μM
Incubation Time: 2 hours; determined infection rates on day 2
Result: Inhibited SARS-CoV-2 infection activity to Caco2 cells.

In Vivo

SARS-CoV-2-IN-27 (CP019) disodium (150 μM, 50 μL; intranasal route; for 2-5 d) shows antiviral activity in vivo against respiratory syncytial virus (RSV) and SARS-CoV-2 in BALB/cJ mice or K18-hACE2 mice, respectively [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Respiratory syncytial virus (RSV) infection of BALB/cJ mice and SARS-CoV-2 infection of K18-hACE2 mice [1]
Dosage: 150 μM, 50 μL
Administration: Intranasal route; single dose; sacrificed BALB/cJ mice on day 5; treated K18-hACE2 mice once again after 7 h and sacrificed mice on day 2
Result: Reduced viral load in the lungs of SARS-CoV-2-infected mice.
Completely abolished SARS-CoV-2 infection of all tested mice without changing body weight of mice.

Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Please store the product under the recommended conditions in the Certificate of Analysis.